Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings Inc (NQ: HRMY )

39.13 -0.66 (-1.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 487,735
Open 40.00
Bid (Size) 39.00 (1)
Ask (Size) 62.97 (2)
Prev. Close 39.79
Today's Range 39.02 - 40.10
52wk Range 18.61 - 40.10
Shares Outstanding 56,834,745
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says
UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's potential for growth, projecting a 19% CAGR for Wakix sales through 2026. 
Via Benzinga
Unveiling 6 Analyst Insights On Harmony Biosciences
Via Benzinga

Performance

YTD
+27.09%
+27.09%
1 Month
+9.45%
+9.45%
3 Month
+28.63%
+28.63%
6 Month
+18.54%
+18.54%
1 Year
+19.41%
+19.41%

More News

Read More
Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Analyst Expectations For Harmony Biosciences's Future
Via Benzinga
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
From Harmony Biosciences
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
Via Benzinga
Key Takeaways From Harmony Biosciences Analyst Ratings
Via Benzinga
7 Cheap Biotech Stocks With Major Upside Potential
Via InvestorPlace
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Via InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
Via InvestorPlace
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Via Benzinga
Topics Cannabis
Exposures Cannabis
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
Via Benzinga
Analyst Ratings For Harmony Biosciences
Via Benzinga
NASDAQ:HRMY stands out as a growth opportunity that won't break the bank.
Via Chartmill
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
Via Benzinga
Topics Earnings
Exposures Financial
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
From Harmony Biosciences
Via GlobeNewswire
Updates: HRMY, MELI, SWAV
Via Talk Markets
Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Harmony Biosciences
Via GlobeNewswire
The 3 Most Undervalued Small-Cap Stocks to Buy in February 2024
Via InvestorPlace
The 3 Most Undervalued Russell 2000 Stocks to Buy in February 2024
Via InvestorPlace
NASDAQ:HRMY: good value for what you're paying.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.